SCHEMBL20239287

SCHEMBL20239287

Cc1cc(CNc2ncc(Cl)cn2)cc(Oc2ccc(CN)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.45
CYP2C9 P11712 2/20 0.44
CYP1A2 P05177 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 3/20 0.40
GLA P06280 1/20 0.40
VNN1 O95497 1/20 0.38
LOXL2 Q9Y4K0 2/20 0.38
MAPK1 P28482 1/20 0.37
ST14 Q9Y5Y6 1/20 0.36
MAOB P27338 2/20 0.35
ALPL P05186 1/20 0.35
ALPG P10696 1/20 0.35
PLAA Q9Y263 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21924533 0.99 DGAT2 (0.44) DGAT2CYP2C9CYP1A2MAPTCYP2C19
SCHEMBL20239247 0.85 LMNA (0.49) DGAT2CYP2C9CYP1A2MAPTCYP2C19
SCHEMBL20239181 0.82 ALDH1A1 (0.45) DGAT2CYP2C9CYP1A2MAPTCYP2C19
SCHEMBL20259251 0.80 ALDH1A1 (0.43) DGAT2CYP2C9CYP1A2MAPTCYP2C19
SCHEMBL20239143 0.76 VNN1 (0.44) DGAT2MAPTLMNAHTTRAB9A
SCHEMBL18249813 0.75 DGAT2 (0.51) DGAT2CYP2C9CYP1A2MAPTCYP2C19
SCHEMBL20239323 0.74 SLC6A4 (0.43) DGAT2RAB9ANPC1VNN1
SCHEMBL20239319 0.74 DGAT2 (0.60) DGAT2CYP2C9CYP1A2MAPTCYP2C19
SCHEMBL20239261 0.74 DGAT2 (0.51) DGAT2CYP2C9CYP1A2MAPTCYP2C19
SCHEMBL20239191 0.74 LOXL2 (0.44) DGAT2VNN1LOXL2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885CYP2C9 2222/4885CYP1A2 1688/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885CYP2C9 1591/4885CYP1A2 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.